NET PROFIT (x1000 EUR)
EMPLOYEES
QuiaPEG Pharmaceuticals AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
3
|
2
|
5 |
| Earnings before taxes |
-866
|
-1,173
|
-1,219 |
| EBITDA |
-519
|
-823
|
-911 |
| Total assets |
1,480
|
1,887
|
1,934 |
| Current assets |
26
|
67
|
165 |
| Current liabilities |
400
|
431
|
1,412 |
| Equity capital |
1,080
|
1,456
|
517 |
| - share capital |
13
|
14
|
14 |
| Employees (average) |
2
|
3
|
4 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
73.0%
|
77.2%
|
26.7% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-58.3%
|
-62.1%
|
-62.8% |
| Current ratio |
6.5%
|
15.5%
|
11.7% |
| Return on equity (ROE) |
-80.2%
|
-80.6%
|
-235.8% |
| Change turnover |
0
|
0
|
-19 |
| Change turnover % | -100% | ||
| Chg. No. of employees |
-1
|
-1
|
-1 |
| Chg. No. of employees % |
-33%
|
-25%
|
-20% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.